# Hanhong

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hanhong

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.hanhonggroup.com
- Total disclosed funding: $14M
- Latest round: Series A (Dec 11, 2023)
- Investors on record: 2

## About

Based in Shanghai, China, and founded in 2003, Hanhong is a biomedical company that focuses on new drug research and development and the drug production industry chain. It has set up a research and development center in Shanghai, and production bases in Shandong, Jiangsu, and Gansu. The company's CEO, Shizhong Ma, graduated from the East China University of Science and Technology. The company received the National SME Innovation Fund project in 2012. As of 2023, the research and development team has 120 people. In December 2023, Hanhong closed a series A funding.

The company is committed to researching, developing, manufacturing, and exporting unnatural amino acids, nucleosides, nucleotides, etc. The products include pharmaceutical intermediates, active pharmaceutical ingredients, and so on. It also provides process development of APIs and intermediates, drug discovery CRO, and other services.

## Funding rounds

- Series A, Dec 11, 2023, $14M — Wisdomont Capital, Golden Lake Capital

## Investors

- Wisdomont Capital (https://capitalatlas.ai/funds/wisdomont-capital) — Series A
- Golden Lake Capital — Series A